Zacks Research Has Positive Outlook for McKesson Q1 Earnings

McKesson Co. (NYSE:MCK - Free Report) - Zacks Research raised their Q1 2026 earnings per share estimates for shares of McKesson in a note issued to investors on Thursday, May 29th. Zacks Research analyst R. Department now forecasts that the company will earn $8.32 per share for the quarter, up from their previous estimate of $8.16. The consensus estimate for McKesson's current full-year earnings is $32.77 per share. Zacks Research also issued estimates for McKesson's Q2 2026 earnings at $8.47 EPS, Q3 2026 earnings at $9.53 EPS, FY2026 earnings at $36.77 EPS, Q2 2027 earnings at $9.60 EPS, FY2027 earnings at $41.44 EPS and FY2028 earnings at $46.19 EPS.

McKesson (NYSE:MCK - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The company reported $10.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $9.83 by $0.29. McKesson had a negative return on equity of 181.26% and a net margin of 0.82%. The business had revenue of $90.82 billion for the quarter, compared to the consensus estimate of $94 billion. During the same period last year, the business posted $6.18 EPS. The business's revenue was up 18.9% compared to the same quarter last year.

MCK has been the subject of several other reports. UBS Group raised their price objective on McKesson from $708.00 to $805.00 and gave the stock a "buy" rating in a research note on Tuesday, April 29th. Wells Fargo & Company lifted their price objective on shares of McKesson from $691.00 to $766.00 and gave the company an "equal weight" rating in a research note on Tuesday. Wall Street Zen upgraded shares of McKesson from a "buy" rating to a "strong-buy" rating in a research note on Friday. Mizuho raised their target price on shares of McKesson from $630.00 to $690.00 and gave the stock a "neutral" rating in a report on Thursday, April 3rd. Finally, Evercore ISI increased their price target on McKesson from $650.00 to $675.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, McKesson currently has an average rating of "Moderate Buy" and an average target price of $692.46.

McKesson Price Performance

NYSE:MCK traded down $6.42 during trading hours on Monday, hitting $715.33. 822,157 shares of the company were exchanged, compared to its average volume of 959,081. The company's 50 day moving average price is $696.36 and its 200-day moving average price is $638.76. The stock has a market capitalization of $89.50 billion, a price-to-earnings ratio of 32.75, a PEG ratio of 1.29 and a beta of 0.53. McKesson has a 52-week low of $464.42 and a 52-week high of $731.00.

Institutional Trading of McKesson

Several institutional investors have recently modified their holdings of MCK. GAMMA Investing LLC lifted its position in McKesson by 75,632.7% in the first quarter. GAMMA Investing LLC now owns 2,393,152 shares of the company's stock valued at $1,610,567,000 after acquiring an additional 2,389,992 shares during the last quarter. Norges Bank purchased a new stake in shares of McKesson in the 4th quarter valued at about $1,200,361,000. Nuveen LLC acquired a new stake in shares of McKesson in the 1st quarter valued at about $475,235,000. Farallon Capital Management LLC purchased a new position in McKesson during the 4th quarter worth approximately $348,044,000. Finally, Wellington Management Group LLP lifted its stake in McKesson by 4,559.6% in the first quarter. Wellington Management Group LLP now owns 427,703 shares of the company's stock valued at $287,840,000 after buying an additional 418,524 shares during the last quarter. Hedge funds and other institutional investors own 85.07% of the company's stock.

Insider Buying and Selling

In related news, CFO Britt J. Vitalone sold 6,336 shares of the business's stock in a transaction that occurred on Thursday, May 22nd. The stock was sold at an average price of $717.30, for a total transaction of $4,544,812.80. Following the completion of the sale, the chief financial officer now owns 14,760 shares in the company, valued at $10,587,348. The trade was a 30.03% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Napoleon B. Rutledge, Jr. sold 543 shares of the stock in a transaction that occurred on Monday, May 19th. The shares were sold at an average price of $726.51, for a total transaction of $394,494.93. Following the completion of the transaction, the chief accounting officer now owns 1,972 shares in the company, valued at $1,432,677.72. This represents a 21.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,747 shares of company stock valued at $9,852,587. Corporate insiders own 0.11% of the company's stock.

McKesson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 1st. Investors of record on Monday, June 2nd will be issued a $0.71 dividend. The ex-dividend date is Monday, June 2nd. This represents a $2.84 annualized dividend and a dividend yield of 0.40%. McKesson's dividend payout ratio is presently 10.99%.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.